a significant trendp < 0.05
Compared with subjects in Q1 of SCr (22.1%), the prevalence of HS in subjects in Q2, Q3 and Q4 was 23.3, 25.3 and 29.3%, respectively, with a significant trend ( p < 0.05).
Compared with subjects in Q1 of SCr (22.1%), the prevalence of HS in subjects in Q2, Q3 and Q4 was 23.3, 25.3 and 29.3%, respectively, with a significant trend ( p < 0.05).
FIB-4 was significantly higher in the HS group than in the non-HS group but did not show an increasing trend with increasing SCr levels.